phase 2 trial of bi 1482694 (hm61713), third-generation tki, in t790m-positive nsclc
Published 8 years ago • 76 plays • Length 2:55Download video MP4
Download video MP3
Similar videos
-
2:14
lux-lung 7: phase 2b trial of first-line afatinib versus gefitinib for egfr mutation-positive nsclc
-
1:48
acquired resistance to third-generation egfr tkis in nsclc
-
19:53
managing progression in egfr-mutant nsclc patients: potential impact of 2nd and 3rd generation tkis?
-
3:34
repeat biopsy in lung cancer patients with egfr mutation
-
5:20
rociletinib/osimertinib for egfr t790m-negative nsclc
-
2:15
phase 2 trial of chemotherapy plus gefitinib as first-line treatment for lung adenocarcinoma
-
5:09
should a third generation egfr inhibitor be first line therapy for egfr mutation-positive nsclc?
-
2:54
pembrolizumab or egfr tyrosine kinase inhibitors in nsclc?
-
2:36
second- and third-generation tkis in egfr-mutated nsclc
-
2:56
non-tki-based treatment options for egfr-mutant lung cancer
-
6:43
sequential afatinib and osimertinib in egfr mutation-positive nsclc patients: updated results
-
24:36
treatment options for egfr t790m negative acquired resistance
-
1:52
phase i trial of bi 764532, a t-cell engager for dll3-positive nec and sclc
-
4:12
ideal treatment duration of tyrosine kinase inhibitors in egfr-mutant nsclc
-
6:15
the clinical use of tyrosine kinase inhibitors in egfr-mutant nsclc
-
2:51
early results from a 3rd gen egfr-tki in advanced nsclc
-
13:06
managing t790-negative egfr-mutated nsclc
-
3:02
osimertinib in advanced egfr t790m-mutant nsclc